(Q33408559)

English

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Francesco Grossi

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Francesco Grossi

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

H J M Groen

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M A Socinski

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

E Juhasz

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Gridelli

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

P Baas

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C A Butts

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

E Chmielowska

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

T Usari

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

P Selaru

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Harmon

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J A Williams

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

F Gao

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

L Tye

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

R C Chao

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

G R Blumenschein

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

20 June 2013

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

24

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2382-2389

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification of chromosomal segment 4q12 in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of the EGFR signaling in tumor microenvironment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet-derived growth factor signaling and human cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23788751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDT212

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23788751%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33408559&oldid=2249119986"